Bliss Gvs Pharma Limited (BLISSGVS) Price & Analysis

Compare

2 Followers

BLISSGVS Stock Chart & Stats

₹144.75

-₹6.85(-3.92%)

At close: Jan 09 4:00 PM EST

₹144.75

-₹6.85(-3.92%)

Day’s Range― - ―

52-Week Range₹105.05 - ₹244.05

Previous CloseN/A

Volume571.01K

Average Volume (3M)104.36K

Market Cap

₹24.32B

Enterprise Value₹22.19B

Total Cash (Recent Filing)₹1.41B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)22.2

Beta1.50

Next Earnings

May 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.28%

Share Statistics

EPS (TTM)2.20

Shares Outstanding105,788,970

10 Day Avg. Volume77,644

30 Day Avg. Volume104,358

Financial Highlights & Ratios

PEG Ratio1.37

Price to Book (P/B)1.20

Price to Sales (P/S)1.56

P/FCF Ratio42.37

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong Balance SheetHigh equity and low leverage provide lasting financial flexibility: they reduce default risk, support investment in manufacturing capacity or regulatory compliance, and allow the company to weather cyclical demand or tender timing without urgent refinancing, sustaining operations over months.

Improving MarginsSustained margin improvement reflects better cost control and pricing execution across formulations. Higher operating margins bolster cash generation potential and buffer profitability against generic pricing pressure, enabling reinvestment or targeted expansion that supports durable earnings quality.

Consistent Revenue GrowthSteady top-line growth indicates continued market demand for its product mix and traction in exports/contract manufacturing. Predictable revenue expansion supports scalable fixed-cost absorption, long-term relationships with buyers, and more reliable planning for capacity and regulatory investments.

Bears Say

Variable Free Cash FlowIrregular free cash flow makes capital allocation and shareholder returns less predictable. Over a multi-month horizon this can constrain funding for capex, regulatory filings, or tender-backed working capital needs, increasing reliance on external funding despite a strong balance sheet.

Inconsistent EBITDA PerformanceVolatility in operating profitability suggests sensitivity to product mix, pricing, or cost swings. Inconsistent EBITDA undermines forecasting accuracy and may signal exposure to competitive tender cycles or uneven margin products, limiting predictability of earnings over the medium term.

Low Dividend Income SupportA very low dividend yield reduces cash return to shareholders and limits appeal to income-focused investors. Over several months this can lessen total-return support and means excess cash is likely retained or reinvested, which may not satisfy investors seeking steady payouts.

Bliss Gvs Pharma Limited News

Bliss GVS Pharma Adds New Step-Down Subsidiary in DR Congo to Deepen African Reach

Bliss Gvs Pharma Limited ( ($IN:BLISSGVS) ) just unveiled an update. Bliss GVS Pharma Limited has expanded its...

27d ago

Bliss GVS Pharma Announces Special Window for Share Transfer Requests

The latest announcement is out from Bliss Gvs Pharma Limited ( ($IN:BLISSGVS) ). Bliss GVS Pharma Limited has...

3M ago

BLISSGVS FAQ

What was Bliss Gvs Pharma Limited’s price range in the past 12 months?

Bliss Gvs Pharma Limited lowest stock price was ₹105.05 and its highest was ₹244.05 in the past 12 months.

What is Bliss Gvs Pharma Limited’s market cap?

Bliss Gvs Pharma Limited’s market cap is ₹24.32B.

When is Bliss Gvs Pharma Limited’s upcoming earnings report date?

Bliss Gvs Pharma Limited’s upcoming earnings report date is May 13, 2026 which is in 79 days.

How were Bliss Gvs Pharma Limited’s earnings last quarter?

Bliss Gvs Pharma Limited released its earnings results on Feb 10, 2026. The company reported ₹2.2 earnings per share for the quarter, beating the consensus estimate of N/A by ₹2.2.

Is Bliss Gvs Pharma Limited overvalued?

According to Wall Street analysts Bliss Gvs Pharma Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bliss Gvs Pharma Limited pay dividends?

Bliss Gvs Pharma Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.28%. See more information on Bliss Gvs Pharma Limited dividends here

What is Bliss Gvs Pharma Limited’s EPS estimate?

Bliss Gvs Pharma Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Bliss Gvs Pharma Limited have?

Bliss Gvs Pharma Limited has 105,788,970 shares outstanding.

What happened to Bliss Gvs Pharma Limited’s price movement after its last earnings report?

Bliss Gvs Pharma Limited reported an EPS of ₹2.2 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.791%.

Which hedge fund is a major shareholder of Bliss Gvs Pharma Limited?

Currently, no hedge funds are holding shares in IN:BLISSGVS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bliss Gvs Pharma Limited

Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. The company also provides other healthcare products, such as balms, creams, lotions, lozenges, nasal inhalers, over the counter products, petroleum jellies, powders, roll-ons, shampoos, soaps, solutions, sprays, syrups, and vaginal washes. In addition, it offers therapeutic products consisting of anti-bacterial, anti-dandruff shampoo, amino acid preparation, iron tonic, antitussive, appetite stimulant, anti-allergic, body supplement, anti-biotic, anti-diabetic, anti-diarrheal, anti-emetic, anti-fungal, anti-haemorrhoidal, anti-helmintic, anti-infective, anti-inflammatory, anti-malarial, anti-microbial, anti-migraine, anti-oxidant, anti-protozoal, ear wax solvent, anti-pyretic, anti-septic, anti-spasmodic, anti-ulcer, and anti-ulcerant; and analgesic, oral rehydration, antacid, anxiolytic, appetizer, cough syrup, erectile dysfunction, haematinic, hand sanitizer, health supplement, insecticide, laryngitis, pharyngitis, laxative, lubricant, mosquito repellant, nasal decongestant, nutritional supplement, moisturizer, prickly heat powder, skin lightening lotion, vaginal contraceptive, vaginal hygiene, and vitamin supplements, as well as medicated, complexion, moisturizing, and total protection soaps. The company also exports its products. Bliss GVS Pharma Limited was incorporated in 1984 and is based in Mumbai, India.